BACKGROUND The incidence, predictors, and prognostic impact of post-discharge bleeding (PDB) after percutaneous
T he optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains a matter of active debate (1) (2) (3) . While DAPT is effective in preventing stent-related and non-stent-related adverse ischemic events (4), prolonged DAPT use is associated with a substantial risk of bleeding and possibly increased mortality (5, 6) . Periprocedural bleeding after PCI has been shown to be associated with increased short-term and long-term morbidity and mortality across the entire clinical spectrum of patients with coronary artery disease treated with PCI (7-9).
In contrast, the impact and contribution of nonperiprocedural bleeding events to late mortality is less certain, especially when compared to post-discharge ischemic events such as myocardial infarction (MI) (4, 10) . Therefore, we sought to evaluate the incidence, predictors, and impact of clinically significant bleeding occurring after hospital discharge following successful DES implantation from the large-scale ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study.
METHODS
STUDY POPULATION. The ADAPT-DES study was a prospective, multicenter registry specifically designed to determine the association between platelet reactivity and stent thrombosis (ST) after DES.
The design and major outcomes of the ADAPT-DES study have been previously described (11) . In brief, an "all-comers" population of 8,582 patients were prospectively enrolled at 11 sites in U.S. and European hospitals. All patients successfully treated with 1 or more DES and who were adequately loaded with aspirin and clopidogrel were eligible for enrollment, regardless of clinical presentation or lesion complexity. The only major exclusion criteria were the occurrence of a major complication during the procedure or before platelet function testing, or if bypass surgery was planned after PCI. Platelet reactivity on aspirin and clopidogrel was assessed after an adequate loading period to ensure full antiplatelet effect using the VerifyNow Aspirin, P2Y 12 , and IIb/IIIa assays (Accumetrics Inc., San Diego, California) (11) .
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Cumulative rates of first post-discharge bleeding event increased over time in all patients; a similar pattern was seen when patients were stratified according to requirement for blood transfusion.
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reported in Online Table 1 . Patients with PDB and blood transfusions were more commonly female, had lower baseline hemoglobin levels, and had a higher proportion of chronic kidney disease at baseline compared to patients with PDB not requiring transfusions.
In reviewing medications used in patients with and without PDB (Online Table 2 ), patients with PDB were more commonly treated with oral anticoagulation with warfarin and proton pump inhibitors, and less commonly on DAPT during the entire study period. Specifically, patients experiencing PDB had higher rates of DAPT disruption because of bleeding (29.0% vs. 1.6%; p < 0.0001).
Also, statin use during 2-year follow-up was lower in patients with PDB, but there were no differences in nonsteroidal anti-inflammatory drug use between groups.
The multivariable adjusted independent predictors of PDB within 2-year follow-up were older age, peripheral artery disease, lower baseline hemoglobin levels, lower baseline PRU, and warfarin use at discharge. Treatment of heavily calcified lesions and bifurcations were also independent predictors of PDB ( Table 2) .
2-YEAR CLINICAL OUTCOMES AND PREDICTORS OF
ALL-CAUSE MORTALITY. Unadjusted 2-year clinical outcomes according to the occurrence of PDB are reported in Table 3 . Patients experiencing PDB had higher crude rates of all-cause mortality (13.0% vs. By multivariable analysis, PDB was the strongest predictor of 2-year mortality (hazard ratio: 5.03; 95% confidence interval: 3.29 to 7.66; p < 0.0001) ( Table 4 ). The effect of PDB with or without transfusion on mortality was similar. The magnitude of the effect of PDB on subsequent mortality was roughly 2.6-fold greater than the effect of PDMI (hazard ratio:
1.92; 95% confidence interval: 1.18 to 3.12; p ¼ 0.009) (p ¼ 0.008 for the effect size of PDB vs. PDMI).
DISCUSSION
The current report, drawn from 8,577 patients undergoing successful PCI with DES, is the largest contemporary study to evaluate the incidence, predictors, and prognostic impact of PDB in an all- Nonetheless, some patients at high risk for thrombotic events, such as those with prior MI, might still benefit from more potent and prolonged DAPT (2, 14) . Choosing those patients who may benefit from shorter versus longer DAPT requires balancing the risk of future atherothrombotic events and Among 444 patients with bleeding and specified source, gastrointestinal bleeding was the most predominant cause of post-discharge bleeding. CNS ¼ central nervous system. (29) . This is consistent with the ADAPT-DES study, which Event rates are Kaplan-Meier estimates reported as % (n). *Wald p value. †Composite of cardiac death, MI, or target lesion revascularization.
MACE ¼ major adverse cardiac event(s); other abbreviations as in Table 1 . Abbreviations as in Table 1 .
(31,32). Finally, although we performed a rigorous multivariable time-adjusted analysis to characterize the relative risks of PDB and PDMI on subsequent mortality, the presence of residual confounders cannot be excluded.
CONCLUSIONS
In an unrestricted PCI population discharged after successful DES implantation, subsequent bleeding complications were not uncommon and were strongly associated with cardiac and all-cause mortality. Pathophysiological mechanisms linking out-of-hospital clinically significant bleeding and mortality after implantation of drug-eluting stents (DES). Several clinical and pharmacological factors increase the propensity for bleeding under dual antiplatelet therapy (DAPT). Hemorrhagic events lead to mortality through a direct effect (central pathway) by reducing circulating blood volume as well as reducing blood oxygencarrying capacity and tissue hypoxia; and through indirect effect (lateral pathways) by increasing the risk for stent thrombosis (because of sudden DAPT discontinuation with rebound in platelet reactivity while the DES is still partially endothelialized) as well as cardiac and noncardiac ischemic events associated with increased thrombogenicity after blood transfusions. Preventing out-of-hospital bleeding after DES implantation may significantly improve survival and long-term prognosis after percutaneous coronary revascularization (PCI).
